Among these, mutations in TP53, APC, KRAS, BRAF, and ATM covered 97.55% of the TCGA population and 83.02% of the validated CRC patients, which were shown to be associated with the development of CRC and can be used as diagnostic features (94). This evidence concerns the gene ATM and colorectal carcinoma.